Edward B. Garon, MD, assistant clinical professor and director of the thoracic oncology program at the David Geffen School of Medicine at the University of California, Los Angeles, and colleagues sought to evaluate pembrolizumab (Merck) — previously known as lambrolizumab and MK-3475 — among patients with previously treated advanced NSCLC.
“We presented the initial data from lung cancer patients at the World Conference on Lung Cancer in Sydney last fall,” Garon told HemOnc Today. “The question at that time was whether the impressive efficacy and tolerable safety profile could be confirmed in a larger population. We have now demonstrated similar results in over 200 additional patients.”
The analysis included 217 patients who were tested for PD-L1 expression using immunohistochemistry (IHC).
Read the report here: http://bit.ly/1kn49ov